NitroMist™ (nitroglycerin lingual aerosol) was approved by the U.S. Food & Drug Administration (FDA) in November 2006 for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. NovaDel is currently investigating commercialization plans for this important drug in markets throughout North America and Europe.

For full prescribing information on NitroMist™, please click HERE. [4.3 mb]

Imitrex®, Zofran® and Requip® are registered trademarks of GlaxoSmithKline. Ambien® is a registered trademark of Sanofi-Aventis. Zanaflex® is a registered trademark of Acordia Therapeutics Inc. ZolpiMist™ and NitroMist™ are trademarks of NovaDel Pharma, Inc. Zensana™ is a pending trademark of Hana Biosciences.